Industry: Pharmaceuticals, Biotechnology
Ilypsa, Inc. is a privately held biopharmaceutical company discovering and developing a pipeline of next-generation renal care pharmaceutical products. Pioneering the use of a proprietary high throughput discovery and development platform created and validated at Symyx Technologies, Inc. (NASDAQ: SMMX), Ilypsa has rapidly created non-absorbed polymeric phosphate and potassium binder compounds to treat chronic kidney disease, and has additional programs in kidney, infectious and metabolic diseases. To date, Ilypsa has raised $46 million in a Series A and Series B round of financing. Investors include The Sprout Group, 5AM Ventures, US Venture Partners, Johnson & Johnson Development Corporation and Delphi Ventures. ( www.ilypsa.com )
Ilypsa , Inc.
Central Expressway Santa Clara
Central Expressway Santa Clara, California 95051
USA
Tel: (408) 215-2800
Fax: (408) 215-2835